Rifaximin enhances the L‑carnitine‑mediated preventive effects on skeletal muscle atrophy in cirrhotic rats by modulating the gut‑liver‑muscle axis

Abstract

The gut-liver-muscle axis is associated with the development of sarcopenia in liver cirrhosis. The present study aimed to illustrate the combined effects of rifaximin and L-carnitine on skeletal muscle atrophy in cirrhotic rats with steatohepatitis. For this purpose, a total of 344 Fischer rats were fed a choline-deficient L-amino acid-defined (CDAA) diet with the daily oral administration of rifaximin (100 mg/kg) and/or L-carnitine (200 mg/kg), and measurements of psoas muscle mass index and forelimb grip strength were performed. After feeding for 12 weeks, blood samples, and liver, ileum and gastrocnemius muscle tissues were harvested. The effects of L-carnitine on rat myocytes were assessed using in vitro assays. Treatment with rifaximin attenuated hyperammonemia and liver fibrosis in the CDAA-fed rats. Moreover, it improved intestinal permeability with the restoration of tight junction proteins and suppressed the lipopolysaccharide (LPS)-mediated hepatic macrophage activation and pro-inflammatory response. In addition, rifaximin prevented skeletal muscle mass atrophy and weakness by decreasing intramuscular myostatin and pro-inflammatory cytokine levels. Moreover, rifaximin synergistically enhanced the L-carnitine-mediated improvement of skeletal muscle wasting by promoting the production of insulin-like growth factor-1 and mitochondrial biogenesis, resulting in the inhibition of the ubiquitin-proteasome system (UPS). The in vitro assays revealed that L-carnitine directly attenuated the impairment of mitochondrial biogenesis, thereby inhibiting the UPS in rat myocytes that were stimulated with LPS or tumor necrosis factor-α. On the whole, the present study demonstrates that the combination of rifaximin with L-carnitine may provide a clinical benefit for liver cirrhosis-related sarcopenia.

The RIVET RCT: Rifamycin SV MMX improves muscle mass, physical function, and ammonia in cirrhosis and minimal encephalopathy

“… 6 On the other hand, no changes in physical SIP or muscle-related changes have been published in humans treated with rifaximin, although translational studies have alluded to them. 35 , 48 Also underlining the local impact of RiVM, the salivary microbiome was unaffected using 16SrRNA sequencing in patients with MHE without prior OHE. In contrast, in patients with MHE and prior OHE, prior studies have shown that microbiota changes with rifaximin are more marked, especially with metagenomics, but RiVM effects have not yet been studied in this population.…”

Effect of l‐Carnitine Supplementation on Osteoarthritis: A Systematic Review

“…[ 47 ] It inhibits skeletal muscle atrophy in cirrhosis or steatohepatitis through the intestinal‐liver‐muscle axis. [ 48 ] l ‐Carnitine is a safe and helpful supplement to treat skeletal muscle sickness, cardiovascular disease, neurological disease, hepatobiliary disease, or pregnancy difficulties, according to several significant evidences.…”

A Comprehensive Review on L-carnitine: A Promising Nutraceutical

“…(Murata et al, 2022) [53] Alzheimer's disease (AD) ALC Mitochondrial membrane potential decline and attenuation in Na+ K+ ATPase functionality, accompanied by reduced mfn1, mfn2, and BCL2 protein concentrations.…”